Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Report Overview

Table of Contents

2622.66

Select License Type

£2,622.67	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£5,245.33	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£7,867.99	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£2,622.67	Add to Wishlist
Change Currency	GBP EURO USD
	Order By Fax

Market	Healthcare and Medical
Report Type	Market Research
Country	Global
Published	27 January 2012
Number of Pages	62
Report Delivery	Email
Delivery Lead Time	1-3 hours, 24 hour max
Publisher	GlobalData
File Format	PDF

Myasthenia gravis therapeutics market is forecast to show slow growth until 2019

GlobalData estimates that the global myasthenia gravis therapeutics market was worth $62.9m in 2011. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.9% over the next eight years to reach $92.2m by 2019. The growth in this market can be attributed to an increase in the myasthenia gravis prevalent population. The increase in the prevalent population is primarily due to a reduction in the mortality rate and the longer life expectancy of myasthenia gravis patients. Although the number of treated patients is increasing, the market is experiencing slow growth due to a lack of efficacious products that can treat the disease as opposed to providing symptomatic relief. The treatment landscape is not going to see any major change in the forecast period due to the lack of promising molecules in the late stage pipeline. The global myasthenia gravis market is expected to remain a low value market during the forecast period due to the domination of generics and off-label drugs.

Current Treatment Options Leave a High Level of Unmet Need

GlobalData's research indicates that the current treatment options are focused on offering symptomatic relief as opposed to treating the disease. The current treatment landscape consists of acetylcholine esterase (AChE) inhibitors (pyridostigmine bromide), steroid (prednisone) and immunosupressants such as azathioprine, cyclosporin A, and mycophenolate mofetil. The available treatment options are moderately successful in meeting the market demand. Even though the mortality rate has declined significantly after the introduction of these drugs, patient satisfaction is still low as the therapies only target symptoms of the disease. This is the reason for the high unmet need in the myasthenia gravis therapeutics market.

The Current Pipeline is Weak and No New Molecules with Novel Mechanisms of Action are Expected to Enter the Market During the Forecast Period (2011-2019)

GlobalData's analysis shows that the current myasthenia gravis therapeutics pipeline is weak. The myasthenia gravis therapeutics pipeline consists of six molecules in the various stages of development.

Phase III contains one molecule, four molecules are in Phase II and one molecule is in the IND filed stage. The late stage pipeline contains only one molecule (prednisone) which is already used as an off label drug for the treatment of myasthenia gravis. The early stage pipeline seems promising, but these drugs are in the early stages of development and will not have an impact on the myasthenia gravis therapeutics market during the forecast period.

Report Scope

The report provides information on the key drivers and challenges of the Myasthenia Gravis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Myasthenia Gravis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Myasthenia Gravis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Myasthenia Gravis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Myasthenia Gravis Therapeutics market

Speak to an Advisor

Call us on
+44 (0) 203 086 8600

Select License Type

£2,622.67	Electronic License Electronic License An electronic version (mostly PDF, but can be Excel or PPT), which is either available for immediate download or will be sent via email by the Publisher of the report. The licencing for an electronic version is for use by the purchaser ONLY.
£5,245.33	Site License Site License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is intended for use by more than one individual, across for example, a site, an office, or a division or country.
£7,867.99	Corporate License Corporate License An electronic version (mostly PDF, but can be Excel or PPT). Where the report(s) is/are intended for use by an organisation in its entirety. For example, if reports are put on an Intranet or if they are distributed or used by more than one office, division, or country operation, then a Corporate Licence is required.

£2,622.67	Add to Wishlist
Change Currency	GBP EURO USD

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Myasthenia Gravis Therapeutics - Introduction

2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Pharmacological Testing - There are two types of pharmacological tests
2.5.2 Serological Testing:
2.5.3 Electrophysiological Testing:
2.5.4 Imaging Tests:
2.6 Treatment and Management Pattern
2.6.1 Pharmacological Therapy
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance

3 Myasthenia Gravis Therapeutics - Market Characterization

3.1 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Global
3.2 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Global
3.3 Myasthenia Gravis Therapeutics Market Size (2006-2011) - The US
3.4 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - The US
3.5 Myasthenia Gravis Therapeutics Market Size (2006-2011) - France
3.6 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - France
3.7 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Germany
3.8 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Germany
3.9 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Italy
3.10 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Italy
3.11 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Spain
3.12 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Spain
3.13 Myasthenia Gravis Therapeutics Market Size (2006-2011) - The UK
3.14 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - The UK
3.15 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Japan
3.16 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Myasthenia Gravis Therapeutics Market
3.17.1 Drivers for the Myasthenia Gravis Therapeutics Market
3.17.2 Barriers for the Myasthenia Gravis Therapeutics Market
3.17.3 Opportunity and Unmet Need Analysis
3.18 Key Takeaway

4 Myasthenia Gravis Therapeutics - Competitive Assessment

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles of the Major Marketed Products in the Myasthenia Gravis Therapeutics Market
4.3.1 Acetylcholinesterase Inhibitor (pyridostigmine)
4.3.2 Steroids (prednisone)
4.3.3 Immunosuppressants
4.3.4 Azathioprine
4.3.5 Cyclosporin A
4.3.6 Mycophenolate Mofetil (MMF)
4.3.7 Venoglobulin-IH
4.4 Key Takeaway

5 Myasthenia Gravis Therapeutics - Pipeline Assessment

5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Myasthenia Gravis Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 Myasthenia Gravis Therapeutics - Phase III Pipeline
5.3.2 Myasthenia Gravis Therapeutics - Phase II Pipeline
5.3.3 Myasthenia Gravis Therapeutics - IND filed Pipeline
5.3.4 Technology Trends Analytic Framework
5.4 Myasthenia Gravis Therapeutics Market -Pipeline by Mechanism of Action
5.5 Myasthenia Gravis Therapeutics - Promising Drugs under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.7 Key Takeaway

6 Myasthenia Gravis Therapeutics - Clinical Trials Mapping

6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Myasthenia Gravis Therapeutics Clinical Trials

7 Strategic Assessment

7.1 Key Events Impacting the Future Market
7.2 Myasthenia gravis Therapeutics: Implications for Future Market Competition

8 Myasthenia Gravis Therapeutics - Future Players

8.1 Company Profiles
8.2 Cytokinetics, Inc.
8.3 Alexion Pharmaceuticals, Inc

9 Myasthenia Gravis Therapeutics - Licensing and Partnership Deals

10 Myasthenia Gravis Therapeutics - Appendix

10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

List of Tables

Table 1: Clinical Classification of Myasthenia Gravis According to Myasthenia Gravis Foundation of America (MGFA)
Table 2: Prevalence of Myasthenia Gravis by Country (G7)
Table 3: Myasthenia Gravis Quality of Life Questionnaire
Table 4: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 5: Myasthenia Gravis Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 6: Myasthenia Gravis Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 7: Myasthenia Gravis Therapeutics Market, The US, Forecasts ($m), 2011-2019
Table 8: Myasthenia Gravis Therapeutics Market, France, Revenue ($m), 2006-2011
Table 9: Myasthenia Gravis Therapeutics Market, France, Forecasts ($m), 2011-2019
Table 10: Myasthenia Gravis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 11: Myasthenia Gravis Therapeutics Market, Germany, Forecasts ($m), 2011-2019
Table 12: Myasthenia Gravis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 13: Myasthenia Gravis Therapeutics Market, Italy, Forecasts ($m), 2011-2019
Table 14: Myasthenia Gravis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 15: Myasthenia Gravis Therapeutics Market, Spain, Forecasts ($m), 2011-2019
Table 16: Myasthenia Gravis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 17: Myasthenia Gravis Therapeutics Market, The UK, Forecasts ($m), 2011-2019
Table 18: Myasthenia Gravis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 19: Myasthenia Gravis Therapeutics Market, Japan, Forecasts ($m), 2011-2019
Table 20: Myasthenia gravis Therapeutics, Phase III Pipeline, 2011
Table 21: Myasthenia gravis Therapeutics, Phase II Pipeline, 2011
Table 22: Myasthenia Gravis Therapeutics, IND Filed Pipeline, 2011
Table 23: Myasthenia Gravis Therapeutics, Clinical Trials by Country, 2011
Table 24: Myasthenia Gravis Therapeutics, Clinical Trials by Phase, 2011
Table 25: Myasthenia Gravis Therapeutics, Clinical Trials by Status, 2011
Table 26: Myasthenia Gravis Therapeutics, Prominent Sponsors, 2011
Table 27: Myasthenia Gravis Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 28: Cytokinetics, Inc., Pipeline, 2011
Table 29: Alexion Pharmaceuticals, Inc., Pipeline, 2011

List of Figures

Figure 1: Normal Neuromuscular Junction
Figure 2: Difference Between Normal and Myasthenic Neuromuscular Junctions
Figure 3: Signs and Symptoms
Figure 4: Repetitive Nerve Stimulation Electrical Tracing
Figure 5: Referral Pathway
Figure 6: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 7: Myasthenia Gravis Therapeutics Market, Global, Forecast ($m), 2011-2019
Figure 8: Myasthenia Gravis Therapeutics Market, The US, Forecast ($m), 2006-2011
Figure 9: Myasthenia Gravis Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 10: Myasthenia Gravis Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 11: Myasthenia Gravis Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 12: Myasthenia Gravis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 13: Myasthenia Gravis Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 14: Myasthenia Gravis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 15: Myasthenia Gravis Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 16: Myasthenia Gravis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 17: Myasthenia Gravis Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 18: Myasthenia Gravis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 19: Myasthenia Gravis Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 20: Myasthenia Gravis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 21: Myasthenia Gravis Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 22: Opportunity and Unmet Need in the Myasthenia Gravis Therapeutics Market, 2011
Figure 23: Myasthenia Gravis Therapeutics, Strategic Competitor Assessment, 2010
Figure 24: Myasthenia gravis Therapeutics - Pipeline by Phase of Development, 2011
Figure 25: Myasthenia Gravis Therapeutics, Technology Trends Analytics Framework, 2011
Figure 26: Myasthenia Gravis Pipeline, Technology Trends Analytics Framework, Description, 2011
Figure 27: Myasthenia Gravis Therapeutics, Pipeline by Mechanism of Action, 2011
Figure 28: Myasthenia Gravis Therapeutics, Clinical Trials by Country, 2011
Figure 29: Myasthenia Gravis Therapeutics, Clinical Trials by Phase (%), 2011
Figure 30: Myasthenia Gravis Therapeutics, Clinical Trials by Status (%), 2011
Figure 31: Myasthenia Gravis Therapeutics, Overall Sponsors (%), 2011
Figure 32: Myasthenia Gravis Therapeutics, Prominent Sponsors (%), 2011
Figure 33: Myasthenia Gravis Therapeutics Market, Drivers and Restraints, 2011
Figure 34: Implications for Future Market Competition in the Myasthenia Gravis Therapeutics Market, 2011
Figure 35: GlobalData Market Forecasting Model 60

Visitor Comments

All Comments

Change Currency

GBP

EURO

USD

Last Viewed

Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Healthcare and Medical Company Profiles

Find latest Healthcare and Medical Company Profiles with up to date financial, strategic, operational, SWOT analysis and product information for the leading healthcare and medical companies.

Competitor Tracking

Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.

Become an Affiliate

Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?

Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.

Custom Research

Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.

Healthcare and Medical	Type	Keywords Phrase All Words Any Word
Microsoft Windows users can hold the CTRL Key to select more than one sector or country at a time. Apple users can hold the CMD Key to do the same.	Country	Industry Sector
Publisher	Order By Relevance Date	Published In

Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Select License Type

Myasthenia gravis therapeutics market is forecast to show slow growth until 2019

Speak to an Advisor

Select License Type

Table of Contents

Visitor Comments

Change Currency

Last Viewed

Healthcare and Medical Company Profiles

Competitor Tracking

Become an Affiliate

Custom Research

News

Market Insights

Companies And Markets

Customer Support

Corporate Accounts

Contact Details

Contrast settings

Text size settings

All
Afghanistan
Africa
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua and Barbuda
Argentina
Armenia
Aruba
Asia
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia-Herzegovina
Botswana
Bouvet Island
Brazil
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Caribbean
Cayman Islands
Central African Republic
Central America
Central Europe
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Conch Republic
Cook Islands
Costa Rica
Croatia
Cuba
Cyprus
Czech Republic
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Eastern Europe
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Europe
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Global
Greece
Greenland
Grenada
Guadeloupe (French)
Guam (USA)
Guatemala
Guernsey
Guinea
Guinea Bissau
Guyana
Haiti
Heard Island and McDonald Islans
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Ivory Coast
Ivory Coast (Cote D`Ivoire)
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kurdistan
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique (French)
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Middle East
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia (French)
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North America
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Island
Poland
Polynesia (French)
Portugal
Puerto Rico
Qatar
Republic of the Congo
Reunion
Romania
Russia
Rwanda
Saint Barthelemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Scandinavia
Schengen countries
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South America
South Georgia and the South Sandwich Islands
South Korea
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste (East Timor)
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands
Wallis and Futuna Islands
Western Sahara
Yemen
Zambia
Zimbabwe

All
Aerospace
Agriculture, Farming & Raw Materials
Automotive and Parts
Business Services
Chemicals
Construction
Consumer Goods
Defence
Energy and Utilities
Environmental
Finance and Banking
Food and Drink
Healthcare and Medical
Industrial
Information Technology
Leisure
Logistics
Media
Paper and Packaging
Publishing and Printing
Real Estate
Retail
Security
Telecommunications
Textiles and Clothing
Transportation
Travel